Application and renewal fees increase for opiate drug wholesalers
Impact
By increasing fees for opiate drug wholesalers, SF2142 aims to generate additional revenue that will be directed into the opiate epidemic response fund, which is utilized for addressing the significant public health issues stemming from opioid misuse. The legislation intends to strengthen the regulatory framework surrounding opiate distribution, ultimately contributing to more robust monitoring and control measures. However, this financial burden on wholesalers could affect the overall cost of medications in the marketplace, potentially impacting public access to necessary treatments.
Summary
SF2142 is a bill aimed at raising application and renewal fees for opiate drug wholesalers and instituting a new fee structure specifically for opiate-related products. The bill modifies existing Minnesota Statutes to establish higher fees for various categories of drug wholesalers, particularly focusing on those handling opiate-containing controlled substances. The fees are intended to better reflect the regulatory costs associated with managing the state's response to the opioid epidemic, and to support the opiate epidemic response fund.
Contention
There are concerns regarding the potential side effects of increased fees on businesses and the healthcare system. Critics argue that higher fees could lead to increased drug prices, which ultimately would be passed on to consumers, thus exacerbating access issues for those in need of pain management or opioid addiction treatment. Furthermore, the elimination of the sunset provision for opioid fees could mean a prolonged financial obligation for drug wholesalers, raising further questions about the long-term economic impact and sustainability of the newly imposed fees.
Similar To
Application and renewal fees increased for opiate drug wholesalers, opiate product fee established for opiate drug wholesalers, and sunset for opioid fees eliminated.
Pharmacy-related license and registration renewal and application procedures modifications, inspection requirements for pharmacy licensure modifications, and fees establishment
Operation of remote pickup sites from which patients may obtain drugs and devices dispensed by a managing pharmacy authorized, and rulemaking authorized.
Use of spread pricing by pharmacy benefit managers prohibited, license application fees increased, permissible sources of income limited, fiduciary duties imposed, and money appropriated.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provides the list to the attorney general to obtain reasons for the cost increases.